This inventor holds 1 USPTO granted patent. Top assignee: Peking University. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Innovations in Hepatitis B Research by Xiaoben Pan
Introduction
Xiaoben Pan is a notable inventor based in Beijing, China. He has made significant contributions to the field of virology, particularly in the study of hepatitis B virus (HBV). His innovative work focuses on utilizing liver cell lines for research purposes, which has implications for drug development and understanding viral infections.
Latest Patents
Xiaoben Pan holds a patent for "Utilizing liver cell line QSG-7701 to be infected with hepatitis B virus." This patent outlines a method that involves directly infecting QSG-7701 cells with purified HBV particles. The process is facilitated by DMSO and/or PEG treatment. The QSG-7701 liver cell line is advantageous as it does not require pre-differentiation induction and is naturally susceptible to HBV infection. This cell line provides near-normal physiological conditions for HBV infection, particularly those characterized by Chinese origin. It is suitable for investigating the life cycle of HBV and is useful for studying viral infection processes and developing targeted drugs.
Career Highlights
Xiaoben Pan is affiliated with Peking University, where he conducts his research. His work has garnered attention for its potential to advance the understanding of hepatitis B and improve therapeutic strategies. His innovative approach to using the QSG-7701 cell line has opened new avenues for research in viral infections.
Collaborations
Xiaoben Pan collaborates with Lai Wei, contributing to the advancement of research in the field of virology. Their combined efforts aim to enhance the understanding of HBV and its implications for public health.
Conclusion
Xiaoben Pan's contributions to hepatitis B research through his innovative use of liver cell lines represent a significant advancement in the field. His work not only aids in understanding viral infections but also paves the way for the development of targeted therapies.